Physician profile
Ralph N Riley
NPI 1861472490
$5,828.10
in general payments reported to CMS, 2019-2025
36 companies · $728 in 2025
The $728 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $874 · 2021: $1,155 · 2022: $608 · 2023: $776 · 2024: $802 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $691.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $534.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $473.83 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $427.61 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.69 | 2020-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $264.29 | 2022-2025 | Rexulti |
| Abbott Laboratories | $250.18 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $247.36 | 2019-2023 | |
| Abbvie INC. | $242.71 | 2020-2025 | |
| Pfizer INC. | $219.69 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $196.62 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $196.46 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $193.34 | 2019-2021 | |
| Dexcom, INC. | $159.94 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $137.78 | 2019-2024 | Arexvy, Shingrix, Bexsero |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $134.35 | 2020-2025 | Nexletol |
| Sunovion Pharmaceuticals INC. | $126.37 | 2019 | |
| Lundbeck LLC | $125.55 | 2023-2025 | Rexulti |
| Amgen INC. | $102.19 | 2019-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $81.48 | 2020-2021 | |
| Amarin Pharma, INC. | $80.99 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $64.15 | 2021-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $56.90 | 2022-2025 | |
| Stryker Corporation | $55.94 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Inspire Medical Systems, INC. | $45.36 | 2025 | Inspire |
| Avanir Pharmaceuticals, INC. | $43.22 | 2019-2022 | |
| Inari Medical, INC. | $41.52 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cranial Technologies, INC | $37.88 | 2023-2024 | Doc Band |
| Optinose US, INC. | $35.17 | 2019-2020 | |
| Edwards Lifesciences Corporation | $30.02 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Phathom Pharmaceuticals, INC. | $27.46 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $24.06 | 2025 | Fanapt, Hetlioz |
| Ethicon US, LLC | $20.25 | 2019 | |
| Acadia Pharmaceuticals INC | $20.13 | 2023 | Nuplazid |
| Nestle Healthcare Nutrition INC. | $19.30 | 2021 | |
| Exact Sciences Corporation | $13.11 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.